NBIX

⚡ 1-Minute Take

Data sources: market data, fundamentals, news providers. Data may be delayed.

Key Statistics

MoonshotScore Breakdown: 54.5/100

📰 Latest News

Neurocrine Biosciences (NBIX) is a leading biopharmaceutical company specializing in neurological and endocrine disorders, offering innovative treatments like INGREZZA for tardive dyskinesia and a robust pipeline, positioning it for sustained growth in a high-demand market with a strong 98.4% gross margin.

About NBIX

Neurocrine Biosciences is a biopharmaceutical company focused on neurological, endocrine, and psychiatric disorders. Their lead product, INGREZZA, treats tardive dyskinesia, and they have a diverse pipeline of clinical programs.

Neurocrine Biosciences, Inc. Company Overview

Neurocrine Biosciences, Inc., founded in 1992 and headquartered in San Diego, California, is a biopharmaceutical company dedicated to discovering, developing, and marketing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's mission is to alleviate suffering for patients and improve lives through premier science and medicine. Neurocrine's journey began with a focus on neuroscience, evolving into a multi-faceted approach addressing a wide range of conditions. The company's portfolio includes INGREZZA (valbenazine), a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, which is the company's lead product and is used for the treatment of tardive dyskinesia. Beyond INGREZZA, Neurocrine offers ONGENTYS, a catechol-O-methyltransferase (COMT) inhibitor for Parkinson's disease; ORILISSA, used in the management of endometriosis; and ORIAHNN, a treatment option for heavy menstrual bleeding associated with uterine fibroids. Neurocrine's commitment to research and development is evident in its robust pipeline, which includes clinical programs targeting pediatric epilepsy, essential tremor, major depressive disorder, anhedonia, and schizophrenia. The company also has strategic collaborations with partners like Takeda, Idorsia, and AbbVie, expanding its reach and capabilities. With a market capitalization of $14.08 billion and a dedicated team of 1800 employees, Neurocrine Biosciences is a significant player in the specialty pharmaceutical market.

Investment Thesis

Neurocrine Biosciences presents a compelling investment opportunity due to its strong market position in neurological and endocrine disorders. The company's lead product, INGREZZA, continues to drive revenue growth, and its diverse pipeline offers significant upside potential. NBIX boasts a high gross margin of 98.4% and a profit margin of 16.0%, reflecting efficient operations and strong pricing power. Upcoming clinical trial results for NBI-921352 in pediatric epilepsy and NBI-1065845 for major depressive disorder could serve as major catalysts. With a P/E ratio of 32.79, NBIX is trading at a premium, but this is justified by its growth prospects and innovative product portfolio. The company's strategic collaborations further de-risk its pipeline and expand its market reach, making it an attractive investment for long-term growth.

Key Financial Highlights

• Market capitalization of $14.08 billion, reflecting strong investor confidence.
• High gross margin of 98.4%, indicating efficient operations and strong pricing power.
• Profit margin of 16.0%, demonstrating profitability and effective cost management.
• Lead product INGREZZA addresses a significant unmet need in tardive dyskinesia.
• Beta of 0.31, suggesting lower volatility compared to the overall market.

Industry Context

Neurocrine Biosciences operates in the specialty pharmaceutical industry, which is characterized by high research and development costs, stringent regulatory requirements, and intense competition. The market for neurological and endocrine disorder treatments is growing due to an aging population and increased awareness of these conditions. Neurocrine competes with companies like Coherus BioSciences (COO), Elan (ELAN), Hologic (HOLX), ICON (ICLR), and Dr. Reddy's Laboratories (RDY). The company differentiates itself through its focus on innovative therapies and strategic partnerships. The industry is also influenced by factors such as patent expirations, pricing pressures, and healthcare reforms.

Quarterly Financial Summary

Source: Company filings. Data may be delayed.

Growth Opportunities

• Expansion of INGREZZA's Market Share: INGREZZA, the company's lead product for tardive dyskinesia, has significant potential for further market penetration. The tardive dyskinesia market is estimated to reach $1.5 billion by 2028. Neurocrine can capitalize on this growth by increasing awareness among healthcare providers and patients, as well as expanding its sales force. The company's strong clinical data and established market presence provide a competitive advantage.
• Development of NBI-921352 for Pediatric Epilepsy: NBI-921352 is a promising product candidate for treating pediatric epilepsy. The global pediatric epilepsy market is projected to reach $5.8 billion by 2027. Positive clinical trial results and regulatory approval could drive significant revenue growth for Neurocrine. The company's expertise in neurology and its established relationships with key opinion leaders in the field position it well for success.
• Advancement of NBI-1065845 for Major Depressive Disorder: NBI-1065845 is being developed for the treatment of major depressive disorder (MDD). The MDD market is one of the largest pharmaceutical markets, with a global value of over $15 billion. Neurocrine's innovative approach to treating MDD, targeting novel mechanisms of action, could differentiate it from existing therapies and capture a significant share of the market.
• Strategic Collaborations and Licensing Agreements: Neurocrine's collaborations with companies like Takeda and AbbVie provide access to new technologies and markets. These partnerships can accelerate the development and commercialization of new products, as well as expand the company's geographic reach. By leveraging external expertise and resources, Neurocrine can enhance its innovation capabilities and reduce its overall risk profile.
• Expansion into New Therapeutic Areas: Neurocrine has the opportunity to expand its focus beyond neurology and endocrinology into other therapeutic areas. This could involve developing treatments for other psychiatric disorders, such as anxiety and bipolar disorder, or exploring new areas such as pain management and oncology. By diversifying its product portfolio, Neurocrine can reduce its reliance on specific markets and increase its long-term growth potential.

Competitive Advantages

• Proprietary drug formulations protected by patents.
• Established brand recognition for INGREZZA.
• Specialized expertise in neurological and endocrine disorders.
• Strategic partnerships with leading pharmaceutical companies.

Strengths

• Strong portfolio of approved products, including INGREZZA.
• Robust pipeline of clinical programs targeting unmet needs.
• High gross margin and profitability.
• Experienced management team with a track record of success.

Weaknesses

• Reliance on INGREZZA for a significant portion of revenue.
• High research and development costs.
• Competition from other pharmaceutical companies.
• Potential for patent expirations and generic competition.

Opportunities

• Expansion of INGREZZA's market share.
• Approval and commercialization of new products in the pipeline.
• Strategic collaborations and licensing agreements.
• Expansion into new therapeutic areas.

Threats

• Regulatory challenges and delays.
• Pricing pressures and healthcare reforms.
• Competition from new and existing therapies.
• Product liability claims.

What NBIX Does

• Discovers novel pharmaceutical compounds.
• Develops treatments for neurological disorders.
• Develops treatments for endocrine disorders.
• Develops treatments for psychiatric disorders.
• Markets and sells pharmaceutical products.
• Conducts clinical trials to evaluate drug efficacy and safety.
• Collaborates with other pharmaceutical companies and research institutions.

Business Model

• Develops and commercializes proprietary pharmaceutical products.
• Generates revenue through product sales.
• Out-licenses certain products or technologies to other companies.
• Collaborates with other companies to develop and commercialize products.

Key Customers

• Patients suffering from neurological disorders.
• Patients suffering from endocrine disorders.
• Patients suffering from psychiatric disorders.
• Healthcare providers who prescribe Neurocrine's medications.
• Hospitals and clinics that use Neurocrine's products.

Competitors

• Coherus BioSciences (COO): Focuses on biosimilars, competing indirectly in some therapeutic areas.
• Elan (ELAN): Acquired by Perrigo, previously focused on neurology.
• Hologic (HOLX): Focuses on women's health, competing in the endometriosis and uterine fibroids markets.
• ICON (ICLR): Provides clinical research services to pharmaceutical companies.
• Dr. Reddy's Laboratories (RDY): Develops and markets generic and specialty pharmaceuticals.

Catalysts

• Upcoming: Clinical trial results for NBI-921352 in pediatric epilepsy expected in Q3 2026.
• Upcoming: Clinical trial results for NBI-1065845 in major depressive disorder expected in Q4 2026.
• Ongoing: Continued expansion of INGREZZA's market share through increased awareness and sales efforts.
• Ongoing: Potential for new strategic collaborations and licensing agreements to expand the product pipeline.

Risks

• Potential: Regulatory setbacks or delays in the approval of new products.
• Potential: Competition from new and existing therapies.
• Ongoing: Reliance on INGREZZA for a significant portion of revenue.
• Ongoing: Patent expirations and generic competition.
• Potential: Product liability claims.

FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Related Stocks in Drug Manufacturers - Specialty & Generic

Browse More

Next Steps